Free Trial
NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

CollPlant Biotechnologies logo
$3.74
+0.06 (+1.63%)
(As of 11/1/2024 ET)

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

Key Stats

Today's Range
$3.64
$3.75
50-Day Range
$3.74
$5.45
52-Week Range
$3.64
$6.99
Volume
2,795 shs
Average Volume
9,552 shs
Market Capitalization
$42.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Strong Buy

Company Overview

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

CollPlant Biotechnologies Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

CLGN MarketRank™: 

CollPlant Biotechnologies scored higher than 40% of companies evaluated by MarketBeat, and ranked 684th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CollPlant Biotechnologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CollPlant Biotechnologies has only been the subject of 2 research reports in the past 90 days.

  • Read more about CollPlant Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CollPlant Biotechnologies is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CollPlant Biotechnologies is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CollPlant Biotechnologies has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CollPlant Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    0.18% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 79.01%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CollPlant Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    CollPlant Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.18% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently increased by 79.01%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

  • Read more about CollPlant Biotechnologies' insider trading history.
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

CLGN Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
CollPlant Biotechnologies Posts Loss In Q2 - Quick Facts
See More Headlines

CLGN Stock Analysis - Frequently Asked Questions

CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN stock has decreased by 41.3% and is now trading at $3.75.
View the best growth stocks for 2024 here
.

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) announced its quarterly earnings data on Tuesday, August, 20th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $0.70 million. CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative trailing twelve-month return on equity of 65.98%.

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

CollPlant Biotechnologies' top institutional investors include Villere ST Denis J & Co. LLC (4.23%) and Pinnacle Associates Ltd. (4.09%).

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

Last Earnings
8/20/2024
Today
11/02/2024
Next Earnings (Estimated)
12/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CLGN
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+193.3%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-7,020,000.00
Net Margins
-2,535.70%
Pretax Margin
-2,535.70%

Debt

Sales & Book Value

Annual Sales
$689,000.00
Book Value
$2.47 per share

Miscellaneous

Free Float
10,355,000
Market Cap
$42.96 million
Optionable
Optionable
Beta
0.31
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CLGN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners